Current Research Studies

Cancer - AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine to Chemotherapy in Infants with Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

Condition or Therapy:

Acute Lymphoblastic Leukemia (ALL), KMT2A (MLL) Gene Rearrangement


Cancer and Blood Disorders
Study Number: AALL15P1

What is the goal of this study?

The goal of this study is to learn if azacitidine, an agent used with chemotherapy in infants, can be safely incorporated into the Interfant-06 chemotherapy backbone. Azacitidine is being used, because it has been shown to improve the cytotoxicity and prevent relapse/resistance in chemotherapy.

Who can join the study?

This study may be a good fit for children who are:

  • Less than 1 year old and,
  • Have newly diagnosed B lymphoblastic leukemia or acute leukemia of ambiguous lineage

What will happen if my child takes part in this study?

You can read more about this study at

Who can I contact for more information?

To learn more, call (206) 987-2106 or send us an email.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Douglas Hawkins